Document:

EX-10.6

 Exhibit 10.6 

Baxter International Inc. 

Equity Plan 
 Incentive
Committee Grant 
 July 1, 2015 
  

	1.	Purpose 

 This Equity Plan (the “Plan”) has been adopted by the Incentive
Committee (the “Incentive Committee”) of the Board of Directors (the “Board”) of Baxter International Inc. (“Baxter”), effective as of July 1, 2015, pursuant to authority granted from time to
time by the Compensation Committee (the “Committee”) of the Board. 
 For avoidance of doubt, all grants made under this Plan shall be made
on or after the date on which Baxter distributes the stock of Baxalta Incorporated, and shall not be subject to adjustment in the manner described in the Employee Matters Agreement between Baxter and Baxalta Incorporated. 

 

	2.	Participants 

 Participants in this Plan (each a “Participant”) shall be
employees of Baxter or its subsidiaries (the “Company”) to whom the Incentive Committee makes awards of equity under this Plan. 
  

	3.	Awards 

 Each grant of equity (an “Award”) shall be made pursuant to and for the
purposes stated in the Company incentive compensation programs or plans (the “Programs”) designated by the Incentive Committee. Unless otherwise indicated, terms defined in the Programs shall have the same meaning in this Plan. 

This Plan provides terms that apply to awards of stock options (“Options”) and restricted stock units (“RSUs”). An award to any
given Participant may be only Options, only RSUs, or any combination of Awards available under the Programs. 
 Participants receive grant communication
letters notifying them of their Awards. The Programs and this Plan provide the definitive terms of each Award; provided that a grant communication letter may include alternative terms with respect to vesting, in which case the vesting terms in the
grant communication letter shall govern. 
 The grant date for an Award shall be the date of approval thereof by the Incentive Committee, or for eligible
French employees, as soon thereafter as practicable pursuant to applicable French law as provided in the attached French Addendum, which shall govern such grants (the “Grant Date”). 

The purchase price for each share of Common Stock subject to an Option shall be the Fair Market Value of a share of Common Stock on the Grant Date. Options
are not intended to qualify as an Incentive Stock Option within the meaning of section 422 of the United States Internal Revenue Code, as amended (the “Code”). 

 Baxter has not selected any country as its home member state under the European Union Directive 2003/71/EC, and
the grant of Awards pursuant to this Plan is simultaneous. 
  

	4.	Options 

 4.1. Except for Options granted to employees of the Company’s
subsidiaries in France, Options shall become exercisable as follows: (i) one-third on the first anniversary of the Grant Date, (ii) one-third on the second anniversary of the Grant Date, and (iii) the remainder on the third
anniversary of the Grant Date. Options granted to employees of the Company’s subsidiaries in France shall become exercisable on the fourth anniversary of the Grant Date. If Options would become exercisable on a date that is not a business day,
they will become exercisable on the next business day. A business day is any day on which the Company’s Common Stock is traded on the New York Stock Exchange. After Options become exercisable (in each case, in whole or in part) and until they
expire, the Options may be exercised in whole or in part in the manner specified by the Committee. Under no circumstances may Options be exercised after they have expired. Shares of Common Stock may be used to pay the purchase price for shares of
Common Stock to be acquired upon exercise of Options or fulfill any tax withholding obligation, subject to any requirements or restrictions specified by the Committee. 

4.2. If a Participant’s employment with the Company terminates before the Participant’s Options becomes exercisable, the Options
will expire when the Participant’s employment with the Company terminates, except (i) in connection with a Qualifying Retirement or death or disability (each as outlined below) or (ii) if the Participant is rehired by the Company
within ninety days of termination, in which case the Participant shall be construed to have been continuously employed by the Company for purposes of vesting and exercise. 

4.3. If a Participant’s employment with the Company terminates after the Participant’s Options become exercisable, the Options will
not expire immediately but will remain exercisable. Subject to Section 4.6, and except in the event of a Qualifying Retirement (as provided in Section 4.4), the Options will expire ninety days after the Participant’s employment with
the Company terminates. If the Participant dies or becomes disabled during the ninety-day period, the Options will expire on the fifth anniversary of the termination date. 

4.4. If the employment of a Participant who is at least 65 years of age, or at least 55 years of age with at least 10 years of employment with
the Company, is terminated other than for Cause or by reason of the Participant’s death or disability (a “Qualifying Retirement”) then (i) if the date of such termination is after the calendar year of the Grant Date, the
Options shall continue to vest as provided in Section 4.1, or (ii) if the date of such termination is in the calendar year of the Grant Date, a portion of the Options shall continue to vest as provided in (i), which portion shall be
determined as follows: (# shares covered by Option award) * (# of months worked in that year, rounded to nearest whole month) / 12. Subject to Section 4.6, the Participant’s Options (whether vesting pursuant to (i) or (ii) or
previously vested) will expire on the fifth anniversary of the termination date. 
 4.5. If the employment of a Participant is terminated
due to death or disability, then (i) if the date of such termination is after the calendar year of the Grant Date, the Options shall vest immediately, or (ii) if the date of such termination is in the calendar year of the Grant Date,

  
 2 

 
a portion of the Options shall vest immediately, which portion shall be determined as follows: (# shares covered by Option award) * (# of months worked in that year, rounded to nearest whole
month) / 12. Subject to Section 4.6, the Participant’s Options (whether vesting pursuant to (i) or (ii) or previously vested) will expire on the fifth anniversary of the termination date. 

4.6. Options that have not previously expired will expire at the close of business on the tenth anniversary of the Grant Date; provided,
however, that Options granted to employees residing in Switzerland on the Grant Date shall expire on the eleventh anniversary of the Grant Date. If Options would expire on a date that is not a business day, they will expire at the close of business
on the last business day preceding that date. A business day is any day on which the Common Stock is traded on the New York Stock Exchange. 

4.7. Except as the Committee may otherwise provide, Options may only be exercised by the Participant, the Participant’s legal
representative, or a person to whom the Participant’s rights in the Options are transferred by will or the laws of descent and distribution. 

4.8. A transfer of employment within the Company will not constitute a termination of employment within the meaning of the Plan. 

4.9. A transfer of employment to a company that assumes an Option or issues a substitute option in a transaction to which Section 424 of
the Code applies will not constitute a termination of employment within the meaning of the Plan. 
 4.10. Except to the extent that it would
cause the Option to be subject to Section 409A of the Code, the Committee may, in its sole discretion and without receiving permission from any Participant, substitute stock appreciation rights (“SARs”) for any or all outstanding
Options. Upon the grant of substitute SARs, the related Options replaced by the substitute SARs shall be cancelled. The grant price of the substitute SARs shall be equal to the Option Price of the related Options, the term of the substitute SARs
shall not exceed the term of the related Options, and the terms and conditions applicable to the substitute SARs shall otherwise be substantially the same as those applicable to the related Options replaced by the substitute SARs. Upon exercise, the
SARs will be settled in Common Stock. 
  

	5.	Restricted Stock Units 

 5.1. RSUs are subject to being earned and vested on the
third anniversary of the Grant Date (as applicable, the “Vesting Date”). If RSUs would become earned and vested on a date that is not a business day, the next business day shall be the Vesting Date. The Company will deliver or
otherwise make available to the Participant within 21/2 months following the applicable Vesting Date one share of Common Stock for each RSU
that vests. 
 5.2. If a Participant’s employment with the Company terminates before an RSU Vesting Date, the RSU will be forfeited
when the Participant’s employment with the Company terminates, except (i) in connection with a Qualifying Retirement or death or disability (each as outlined below), or (ii) if the Participant is rehired by the Company within ninety
days of termination, in which case the Participant shall be construed to have been continuously employed by the Company for purposes of vesting and payout. 

  
 3 

 5.3. If the employment of a Participant terminates in a Qualifying Retirement then (i) if
the date of such termination is after the calendar year of the Grant Date, the RSUs will remain eligible for payout on the terms provided in Section 5.1, or (ii) if the date of such termination is in the calendar year of the Grant Date a
portion of the RSUs shall remain eligible for payout on the terms provided in Section 5.1, which portion shall be determined as follows: (# RSUs awarded) * (# of months worked in that year, rounded to nearest whole month) / 12. 

5.4. If the employment with the Company of a Participant is terminated due to death or disability, the RSUs shall vest as follows: (i) if
the date of such termination is after the calendar year of the Grant Date, all the RSUs shall pay out within sixty days, or (ii) if the date of such termination is in the calendar year of the Grant Date a portion of the RSUs shall pay out as
provided in (i), which portion shall be determined as follows: (# RSUs awarded) * (# of months worked in that year, rounded to nearest whole month) / 12. 

5.5. The RSUs shall not be transferable and may not be sold, assigned, pledged, hypothecated or otherwise encumbered. 

5.6. A transfer of employment within the Company will not constitute a termination of employment within the meaning of the Plan. 

5.7. Until the shares of Common Stock have been delivered or otherwise made available as provided in Section 5.1, the Participant shall
not be treated as a shareholder as to those shares of Common Stock relating to the RSUs. Notwithstanding the foregoing, the Participant shall be permitted to receive additional RSUs with respect to the RSUs based upon the dividends and distributions
paid on shares of Common Stock to the same extent as if each RSU were a share of Common Stock, which additional RSUs shall be delivered or made available at the same time and to the same extent as the RSUs to which they relate or as otherwise
determined by the Company. 
  

	6.	Change in Control 

 Except as otherwise provided in the last sentence of this Section 6,
notwithstanding any other provision of the Programs or this Plan (and in lieu of vesting at the times otherwise provided in the Programs), if the termination of employment of a Participant occurs upon or within twenty-four (24) months following
a Change in Control by reason of (a) termination by the Company for reasons other than for Cause or (b) termination by the Participant for Good Reason, then all RSUs and Options shall become immediately vested and all Options immediately
exercisable. The provisions of this Section 6 shall not apply to any Award granted under the Baxter International Inc. 2015 Incentive Plan, or any subsequent Program adopted by Baxter that includes a provision dealing with the effect of a
Change in Control, and the treatment of Awards granted under any such Program upon a Change in Control shall be governed exclusively by the terms of such Program. 
  

	7.	Additional Definitions 

 For purposes of the Plan, the following capitalized terms shall have the
meanings provided below. 

  
 4 

 “Affiliate” shall have the meaning set forth in Rule 12b-2 promulgated under Section 12 of
the Securities Exchange Act of 1934, as amended. 
 “Cause” means (i) the willful and continued failure by the Participant to
substantially perform his duties with the Company that has not been cured within 30 days after written demand for substantial performance is delivered by the Company, which demand specifically identifies the manner in which the Participant has not
substantially performed (other than any such failure resulting from the Participant’s incapacity due to physical or mental illness), (ii) the willful engaging by the Participant in conduct which is demonstrably and materially injurious to
the Company, monetarily or otherwise, or (iii) the engaging by the Participant in egregious misconduct involving serious moral turpitude, determined in the reasonable judgment of the Committee. For purposes hereof, no act, or failure to act, on
the Participant’s part shall be deemed “willful” unless done, or omitted to be done, by the Participant not in good faith and without reasonable belief that such action was in the best interest of the Company. Notwithstanding the
foregoing, if a Participant is a party to a Change in Control Agreement, “Cause” with respect to such Participant shall have the meaning given to such term in the Change in Control Agreement. 

“Change in Control” means the first to occur of any of the following: (i) any Person is or becomes the beneficial owner (as defined in
Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of Baxter (not including in the securities beneficially owned by such Person any securities acquired directly from the Company or its Affiliates) representing 30% or more of
the combined voting power of Baxter’s then outstanding securities, excluding any Person who becomes such a beneficial owner in connection with a merger or consolidation of Baxter or any direct or indirect subsidiary of Baxter with any other
corporation immediately following which the individuals who comprise the Board immediately prior thereto constitute at least a majority of the board of directors of (A) any parent of Baxter or the entity surviving such merger or consolidation
or (B) if there is no such parent, of Baxter or such surviving entity; (ii) the following individuals cease for any reason to constitute a majority of the number of directors then serving: individuals who, on the Grant Date, constitute the
Board and any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of
Baxter) whose appointment or election by the Board or nomination for election by Baxter’s shareholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors on
the Grant Date or whose appointment, election or nomination for election was previously so approved or recommended: (iii) there is consummated a merger or consolidation of Baxter or any direct or indirect subsidiary of Baxter with any other
corporation or other entity, other than a merger or consolidation immediately following which the individuals who comprise the Board immediately prior thereto constitute at least a majority of the board of directors of (A) any parent of Baxter
or the entity surviving such merger or consolidation or (B) if there is no such parent, of Baxter or such surviving entity: or (iv) the shareholders of Baxter approve a plan of complete liquidation or dissolution of Baxter or there is
consummated an agreement for the sale or disposition by Baxter of all or substantially all of Baxter’s assets, other than a sale or disposition by Baxter of all or substantially all of Baxter’s assets immediately following which the
individuals who comprise the Board immediately prior thereto constitute at least a majority of the board of directors of (A) any parent of Baxter or of the entity to which such assets are sold or disposed or (B) if there is no such parent,
of Baxter or such entity. 

  
 5 

 “Change in Control Agreement” means an employment agreement, change in control agreement or
plan, severance agreement or plan, or other agreement between the Company and a Participant or Company plan covering a Participant that provides for benefits upon termination for good reason or cause in connection with a change in control of Baxter
and that has been approved by the Board or the Committee. 
 “Good Reason” means the occurrence (without the Participant’s express
written consent) of any of the following which occur on or after a Change in Control: (i) reduction by the Company in the Participant’s annual base salary as in effect on the Grant Date or as the same may be increased from time to time;
(ii) the relocation of the Participant’s principal place of employment to a location more than fifty (50) miles from the Participant’s principal place of employment immediately prior to the Change in Control or the Company’s
requiring the Participant to be based anywhere other than such principal place of employment (or permitted relocation thereof) except for required travel on the Company’s business to an extent substantially consistent with the
Participant’s business travel obligations as in effect immediately prior to the Change in Control; or (iii) the failure by the Company to pay to the Participant any portion of the Participant’s current compensation or to pay to the
Participant any portion of an installment of deferred compensation under any deferred compensation program of the Company, within seven (7) days of the date such compensation is due. Notwithstanding the foregoing, if a Participant is a party to
a Change in Control Agreement, “Good Reason” with respect to such Participant shall have the meaning given to such term in the Change in Control Agreement. 

“Person” shall have the meaning given in Section 3(a)(9) of the Securities Exchange Act of 1934, as amended, as modified and used in
Sections 13(d) and 14(d) thereof, except that such term shall not include (i) Baxter or any of its subsidiaries, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of Baxter or any of its Affiliates,
(iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the shareholders of Baxter in substantially the same proportions as their ownership of
stock of Baxter. 
  

	8.	Program Controls 

 Except as specifically provided in the Plan, in the event of any inconsistency
between the Plan and the Programs, the Programs will control, but only to the extent such provisions will not violate the provisions of section 409A of the Code. 

  
 6 

 BAXTER INTERNATIONAL INC. 

French Addendum 
  

	1.	PURPOSES OF THIS ADDENDUM 

 This Addendum (the “French Addendum”) to the Baxter
International Inc. Quarterly Equity Plan, Incentive Committee Grant (the “Plan”) provides the terms for Options granted to Eligible French Participants (as defined below). 

Except as otherwise expressly provided in this French Addendum, the terms of awards shall be as provided in and governed by the Plan. Terms not otherwise
defined herein shall have the meanings provided in the Plan. 
 Awards granted under this French Addendum are restricted to Options satisfying the
conditions set forth in the French Commercial Code (articles L.225-177 to L.225-I85) and such Options are intended to be eligible for a tax-favored regime. 
  

	2.	PARTICIPANTS 

 Options may only be granted under this French Addendum to employees
(“Eligible French Participants”) of companies in which the Company holds at least ten percent (10%) of the voting rights or equity, directly or indirectly. No individual in France holding more than ten percent of the issued
equity of the Company can be an Eligible French Participant. 
  

	3.	AWARDS 

  

	 	3.1.	Grant of Options 

 No Options may be granted under this French Addendum: (a) before the end of a period of
twenty (20) trading days following (i) a dividend record date for any dividend or (ii) an agreement by the shareholders of the Company to increase the issued share capital of the Company; (b) within a period of ten
(10) trading days before and after the publication of consolidated accounting results of the Company (e.g., the filing of an Annual Report on Form 10-K); or (c) within a period beginning with the date upon which the Company’s
executive officers become aware of any nonpublic information that, if it were to become publicly known, would reasonably be expected to affect the value of the Company’s shares of Common Stock and ending ten (10) trading days after that
information has been publicized. 
 The Grant Date shall be the date as of which the Committee approves grants to Eligible French Participants or as soon
thereafter as possible, ensuring that the above restrictions are respected. The acquisition price of shares subject to Option (the “Option Price”) shall be established on the Grant Date. 

 

	 	3.2.	Option Price 

 The Option Price shall be the greatest of (a) the Fair Market Value on the Grant Date;
(b) eighty percent (80%) of the average opening price of a share of Common Stock over the twenty (20)

 
trading days preceding Grant Date; and (c) if treasury shares are used to satisfy exercise of the Option, eighty percent (80%) percent of the average repurchase price per share paid by
the Company for such treasury shares. 
  

	 	3.3.	Shares Available for Option 

 In no event shall the number of shares of Common Stock subject to outstanding
unexercised Options granted pursuant to this French Addendum give right to subscribe shares exceeding one-third (1/3) of the Company’s share capital. 
  

	 	3.4.	Options Giving Right to Purchase Previously Issued Shares 

 If an Option provides a right to purchase previously
issued shares, the Company shall procure sufficient shares to satisfy the exercise of such Option at least one day prior to the Participant’s having the right to exercise such Option. 

 

	 	3.5.	Characteristics of Shares 

 Shares issued pursuant to Options shall be non-bearer shares or shares held in an
identifiable account. 
  

	 	3.6.	Substitution of SARs for Options 

 Neither SARs nor any other incentive may be substituted for Options granted
pursuant to this French Addendum. 
  

	 	3.7.	Adjustment to Option Price 

 The number of Options and the Option Price for grants made pursuant to this French
Addendum may be adjusted in connection with changes in capital operations described in article L.225-181 of the French Commercial Code so that economic rights are maintained. 
  

	4.	VESTING AND EXERCISE OF OPTIONS 

  

	 	4.1.	Vesting 

 Options granted pursuant to this French Addendum shall first become exercisable on the fourth
(4th) anniversary of the Grant Date. 
  

	 	4.2.	Non-Transferability of Options — Death of the Participant 

 Options granted pursuant to this French
Addendum shall be non-transferable and can only be exercised by the Eligible French Participant, or, in the event of the Eligible French Participant’s death, the heirs may exercise the Options (where previously vested or not) within six months
of the date of the Eligible French Participant’s death. 

  
 8Supplement
to Agreement of the Executive Chairman

 

This
supplement (this “Supplement”) is dated as of June 30, 2015.

 

Reference
is hereby made to that certain Agreement (the “Agreement”) that was made as of February 7, 2014 by and between
CARDAX, INC., a Delaware corporation (the “Company”), and Nicholas Mitsakos, an individual (the “Executive
Chairman”). Capitalized terms used in this Supplement that are not otherwise defined in this Supplement shall have the
respective meanings ascribed thereto in the Agreement.

 

For
good and valuable consideration, the receipt and sufficiency is hereby acknowledged, the parties to the Agreement hereby agree
to amend and supplement the Agreement as provided in this Supplement.

 

1.
Compensation. 

 

1.1
Effective April 1, 2015, Section 2 of the Agreement is amended to delete such section in its entirety and replace such section
with the following:

 

2.
Compensation. The aggregate annual compensation of the Executive Chairman shall be equal $150,000. Such compensation shall
be paid quarterly in arrears as of the last day of each fiscal quarter in equity of the Company in the form of a grant of shares
of common stock, par value $0.001 per share (“Common Stock”) or non-qualified stock options (“Options”)
under the Company’s 2014 Equity Compensation Plan, as amended or supplemented (the “Plan”) as follows:

 

2.1
The Executive Chairman shall provide a notice to the Company of his election to receive a grant of shares of Common Stock or Options
not later than the business day that is at the end of the applicable fiscal quarter or such other time as mutually agreed by the
Company and the Executive Chairman. If a notice is not duly and timely received, then the Executive Chairman shall be deemed to
have elected to receive the compensation for such quarter in Options.

 

2.2
If the Executive Chairman elects to receive compensation for any quarterly period in a grant of Common Stock, then the number
of shares that shall be issued will equal the amount payable during such quarter (i.e., $37,500) divided by the volume weighted
average closing price (“VWAP”) for the 20 trading days ending on the last trading day of such quarter.

 

2.3
If the Executive Chairman elects to receive compensation for any quarterly period by the grant of Options, then

 

2.3.1
The number of shares of Common Stock that may be purchased by such Option shall be determined so that the Quarterly Value as of
the end of such quarter of such Options is equal to the amount payable for such quarter (i.e., $37,500).

 

    	1

    	 

    

 

2.3.2
The initial exercise price for such Options will be the closing price of the Common Stock as of the end of the applicable quarter,
which shall be the date that any such Options are granted; provided, that if such closing price is 90% or less of the closing
price of the immediately prior trading date, then the initial exercise price shall be the greater of (x) the closing price as
of the end of such quarter or (y) the VWAP for the 5 trading days ending on the last trading day of such quarter.

 

2.3.3
For the purposes of this Agreement, the term “Quarterly Value” shall mean the value as of the end of the applicable
quarter using the 20 day VWAP as of the end of such quarter. The value of the Options will be determined by the Company using
a Black Scholes model for such VWAP for the 20 trading days ending on the last trading day of the applicable quarter with such
other factors as are appropriate to accurately calculate the value of the Options as of the end of quarter.

 

2.3.4
Options that are granted under this Section 2 shall be fully vested, have the same anti-dilution protection as provided in the
Company’s Class A Warrants and have a 5 year term from the last day of the applicable quarter.

 

2.
Payment of 2015 Arrears.

 

2.1
The amount of the accrued and unpaid fees payable to the Executive Chairman accruing from January 1, 2015 to March 31, 2015 is
equal to $55,385. Such amount shall be discharged in full by the Company granting to the Executive Chairman on June 30, 2015 a
non-qualified stock option to purchase 263,736 shares of Common Stock with an initial exercise price equal to $0.32 per share.
Such option shall be fully vested, have the same anti-dilution protection as provided in the Company’s Class A Warrants
and have a 5 year term.

 

2.2
The Executive Chairman hereby waives all payment defaults with respect to the service fees described in Section 2.1 of this Supplement,
and any rights related thereto.

 

3.
Ratification. 

 

3.1
The terms and conditions of the Agreement as modified by this Supplement are acknowledged and agreed to be in full force and effect.

 

    	2

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed and delivered this Supplement as of the date first written above.

 

	 	COMPANY:
	 	 
	 	Cardax,
    Inc.
	 	 
	 	By:	/s/
    David G. Watumull
	 	Name:	David G. Watumull
	 	Title:	President and
    CEO

 

	 	EXECUTIVE
    CHAIRMAN:
	 	 
	 	/s/
    NICHOLAS MITSAKOS
	 	NICHOLAS MITSAKOS,
    Individually

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]